Small Animal Studies

摘要共享资源11：小动物研究（SAS-SR） 小动物研究共享资源（SAS-SR）包括两个部分：小动物成像 核心和动物肿瘤模型组件。这一综合资源提供了卓越的优质服务 City of Hope Comprehensive Cancer Center（COHCCC）会员， 癌症生物学研究、抗癌药物开发和干细胞治疗开发。 SAS-SR的具体目标： 目标1.为动物实验的设计、执行和分析提供咨询。 目标2.促进新动物模型和新型非侵入性体内成像的开发 支持癌症研究的技术。 目标3.保持进行高质量动物研究所需的资源和专业知识 标准，并符合当地，州和国家指导方针。 SAS-SR的小动物成像部分提供咨询，先进的成像设备， 影像服务，COHCCC成员的实践培训，以及对协议和赠款准备的支持。 成像实验室的现有系统包括五个生物发光/荧光光学成像单元 (Lago/Lago X/Ami HTX，来自Spectral Instruments Imaging和PerkinElmer IVIS），GNEXT PET/CT 仪器（SofieBiosciences）、7T MRI/PET（MRsolutions）和超声成像仪（VisualSonics VEVO）。 这些系统支持基于分子的成像，以允许监测细胞过程和非细胞过程。 治疗剂的药代动力学和药效学的侵入性评估。动物肿瘤 SAS-SR的模型部分建立了多种癌症的患者源性异种移植（PDX）模型 并开发了下一代人源化小鼠模型，用于研究 癌症免疫治疗和体内药物代谢/毒性研究。PDX模型的开发支持 精确医学允许研究人员评估个体的肿瘤生长和治疗反应 患者动物肿瘤模型部分还提供专门的药物递送服务， 体内程序，并支持方案编制和赠款开发。SAS-SR由Dr. 免疫学与治疗诊断学系教授兼系主任安娜·吴（Anna Wu）和副教授吴军（Jun Wu）博士 比较医学研究教授。活动得到高素质人员的支持， 维护和操作仪表。 2017 - 21年按收入百分比计算的会员利用率：总计96.7（11.2 MCBC，33.4 DCT，26.6 CI，25.5 HM） 成员出版物：88，28影响因子> 10 支持的赠款：共78项（3项ACS，8项CIRM，8项DoD，4项LLS，33项NCI，46项NIH（32项R01，1项U01））

Abstract Shared Resource 11: Small Animal Studies (SAS-SR) The Small Animal Studies Shared Resource (SAS-SR) comprises two components: the Small Animal Imaging Core and the Animal Tumor Models component. This combined resource provides exceptional quality services for City of Hope Comprehensive Cancer Center (COHCCC) Members for basic and translational preclinical studies in cancer biology, anti-cancer drug development, and stem cell therapeutic development. Specific Aims for SAS-SR: Aim 1. Provide consultation for the design, performance, and analysis of animal experiments. Aim 2. Facilitate the development of new animal models and novel non-invasive in vivo imaging technology in support of cancer research. Aim 3. Maintain the resources and expertise necessary for conducting animal research with high quality standards and in compliance with local, state, and national guidelines. The Small Animal Imaging component of the SAS-SR provides consultation, advanced imaging equipment, imaging services, hands-on training for COHCCC Members, and support for protocol and grant preparation. Current systems in the Imaging Laboratory include five units for bioluminescence/fluorescence optical imaging (Lago/Lago X/Ami HTX from Spectral Instruments Imaging and a PerkinElmer IVIS), a GNEXT PET/CT instrument (SofieBiosciences), a 7T MRI/PET (MRsolutions), and ultrasound imager (VisualSonics VEVO). These systems support molecular-based imaging to allow for the monitoring of cellular processes and the non- invasive assessment of pharmacokinetics and pharmacodynamics of therapeutic agents. The Animal Tumor Models component of the SAS-SR has established patient-derived xenograft (PDX) models of multiple cancers in collaboration with COH faculty and has developed next-generation humanized mouse models for research in cancer immunotherapy and in vivo drug metabolism/toxicity studies. The development of PDX models supports precision medicine allowing investigators to evaluate tumor growth and therapeutic response for individual patients. The Animal Tumor Models component also provides specialized drug delivery services, training for in vivo procedures, and support for protocol preparation and grant development. The SAS-SR is co-directed by Dr. Anna Wu, Professor and Chair, Department of Immunology and Theranostics and by Dr. Jun Wu, an Associate Research Professor of Comparative Medicine. Activities are supported by highly qualified personnel that maintain and operate the instrumentation. Members Utilization by %Revenue 2017–21: 96.7 Total (11.2 MCBC, 33.4 DCT, 26.6 CI, 25.5 HM) Publications by Members: 88, 28 with Impact Factor >10 Grants Supported: 78 Total (3 ACS, 8 CIRM, 8 DoD, 4 LLS, 33 NCI of 46 NIH (32 R01, 1 U01))